/
Oncology
Selected Advanced Solid Tumors
13
Pipeline Programs↗
6
Active Trials↗
19
Companies Involved↗
Selected Advanced Solid Tumors is an emerging landscape with 13 programs across 19 companies. The most active players are AstraZeneca, MediLink Therapeutics (Suzhou) Co., Ltd., AskGene Pharma, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 16
Phase 27
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
10 of 11 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 92% of 13 pipeline programs.
Analysis
Trial Status
29
clinical trials
Completed15 · 52%
Terminated7 · 24%
Active, not recruiting3 · 10%
Recruiting3 · 10%
Unknown status1 · 3%
Clinical Trials
Trial Activity
29 trials
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Completed·—·Phase 1·NCT01449058·139 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)